Bio-Techne Corporation (TECH) earnings on August 12, 2026
More Bio-Techne Corporation earnings
Prior outlook: Pessimistic Outcome: Missed
Bio-Techne's results met or beat expectations, and the stock edged slightly higher.
TECH price around the earnings
72.23
Change: +0.1%
2026-08-12, 20:00 UTC
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: Pessimistic Outcome: Missed
- Thesis published
- Results released
Analysts cautious — risk outweighs reward
Analysts project a decline with negative revenue growth and a weak earnings history, and the outlook has worsened sharply. The pessimistic scenario is driven by the technical structure, with sentiment also negative.
Context analyzed before publication
- Summary
- Analysts cautious — risk outweighs reward
- Playbook
- The stock is underperforming the market, with a flat revenue trend and a consensus rating of 'hold' implying a slight downside. Recent downgrades and a weak earnings beat rate add to the negative backdrop.
- Trend
- Analyst outlook deteriorating sharply
Analysts
Drivers
-
Analysts
Negative
The consensus rating is 'hold' with a target implying -3.4% downside, and several banks have recently downgraded the stock.
Evidence
- Analyst consensus
- Hold
- Consensus average (1-5)
- 2.71
- Analysts covering the stock
- 11
- Average price target
- 69.73
- Lowest price target
- 50
- Highest price target
- 73
- Upside to price target
- -3.4%
- Quarterly earnings growth
- 126%
- Revenue growth
- -1.5%
- Forward EPS
- 2.04
- Trailing EPS
- 0.7
- Analyst moves in the last 60 days
- 7
- Strong buy: 0
- Buy: 2
- Hold: 12
- Sell: 0
- Strong sell: 0
- Strong buy
- 0
- Buy
- 2
- Hold
- 12
- Sell
- 0
- Strong sell
- 0
- July 9, 2026 · RBC Capital: Downgrades rating (Outperform → Sector Perform)
- June 30, 2026 · TD Cowen: Downgrades rating (Buy → Hold)
- June 30, 2026 · Benchmark: Downgrades rating (Buy → Hold)
- June 29, 2026 · Citigroup: Downgrades rating (Buy → Neutral)
- June 26, 2026 · Stephens & Co.: Downgrades rating (Overweight → Equal-Weight)
- June 26, 2026 · William Blair: Downgrades rating (Outperform → Market Perform)
- June 26, 2026 · Baird: Maintains rating (Neutral → Neutral)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 99%
News
There is no news coverage available for this event.
Technicals
Drivers
-
Technical
Neutral
The stock has shown minimal movement over the past two weeks and a month, with no clear trend.
Evidence
- Price when the context was analyzed
- 72.16
- Average true range (ATR)
- 0.5%
- Distance to 52-week high
- -0.2%
- 14-day change (14d)
- +0.1%
- 30-day change (32d)
- +1.2%
- 30-day relative strength
- -0.8%
- SPY change (32d)
- +2.1%
- Nearest support
- 71.92
- Distance to nearest support
- 0.3%
- Nearest resistance
- 72.32
- Distance to nearest resistance
- 0.2%
- Volume accumulation ratio (14d / 46d)
- 0.71
- Mid: 71.92 (0.3% away, 0.72 ATR, 28 touches)
- Mid: 71.51 (0.9% away, 1.95 ATR, 24 touches)
- Mid: 71.23 (1.3% away, 2.82 ATR, 17 touches)
- Mid: 72.32 (0.2% away, 0.5 ATR, 16 touches)
- Minor: 72.75 (0.8% away, 1.8 ATR, 8 touches)
- Minor: 73.19 (1.4% away, 3.13 ATR, 6 touches)
Trends
Drivers
-
Macro & trends
Negative
Revenue growth is flat at -0.01%, and the stock is underperforming the S&P 500 by -0.85%.
Evidence
- Average earnings surprise
- +2.6%
- May 6, 2026: actual EPS 0.53 vs estimate 0.53 (surprise -0.8%)
- February 4, 2026: actual EPS 0.46 vs estimate 0.43 (surprise +5.8%)
- November 5, 2025: actual EPS 0.42 vs estimate 0.42 (surprise -0.4%)
- August 6, 2025: actual EPS 0.53 vs estimate 0.5 (surprise +5.8%)
Expected move
Drivers
-
Past earnings
Negative
The company has beaten earnings only half the time, with a small average surprise, making its history unreliable.
- Implied move
- +0.2%
- Source
- Options chain
Reactions over its last 20 earnings
- Median move
- 3.8%
- 75th percentile move
- 7.3%
- 90th percentile move
- 10.1%
- Up / down moves
- 11 / 9
- Average up move
- +5.7%
- Average down move
- -5.2%
Monitoring and close
What Bio-Techne Corporation reported
- Status
- Finished
| Actual EPS | 0.52 |
|---|---|
| EPS estimate | 0.52 |
| EPS surprise | +0.1% |
| Revenue | $321 million |
| Revenue estimate | $315 million |
| Revenue surprise | +2.1% |
Bio-Techne surprised with Q2 sales of $321.2M, beating estimates, while its non-GAAP profit of $0.52 per share met expectations.
Sources (3)
- Bio-Techne (NASDAQ:TECH) Surprises With Q2 CY2026 Sales (opens in a new tab) — StockStory
- Bio-Techne reported adjusted EPS of $0.52, in line with expectations, and revenue of $321.191M, beating the $314.679M estimate. — Benzinga
- Bio-Techne Q4 Adj. EPS $0.52, Inline, Sales $321.191M Beat $314.679M Estimate (opens in a new tab) — Benzinga
Pre-market second reading after the results
- Verdict
- In line with expectations
Heading into the open, results beat expectations on both earnings and revenue, and the price is indicating +0.2% pre-market, a move below the stock's usual reaction (about 4%). The figures don't confirm the prior scenario: that move is too small to draw conclusions from.
How the stock reacted
- Outcome
- Missed
- Consolidated
- +0.1%
- Max favorable move (MFE)
- 0%
- Max adverse move (MAE)
- 0.3%